International Business Machines Corporation (NYSE:IBM) [Trend Analysis] surged reacts as active mover, shares surge 0.13% to traded at $165.73 and the percentage gap between open changing to regular change was 0.32%. Blockchain, cognitive computing and cloud are some of the technologies that will shape the finance industry the most in the digital age, banking and technology chief executives told a financial conference on Monday.
IBM Corp’s president and chief executive GinniRometty said that cognitive computing, or computer systems that can mimic the way the human brain works, will be the “ultimate way” finance firms will become more competitive in the future. “I think the advantage is going to go to who has the best insights,” Rometty told delegates.Over the past few years financial institutions have been struggling to take advantage of vast amounts of data that they store, which is held unevenly across their numerous databases. The firm’s current ratio calculated as 1.20 for the most recent quarter. The firm past twelve months price to sales ratio was 1.97 and price to cash ratio remained 15.65. As far as the returns are concern, the return on equity was recorded as 76.40% and return on investment was 23.40% while its return on asset stayed at 10.20%. The firm has total debt to equity ratio measured as 2.50.
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 1.23% to close at $23.39 with the total traded volume of 154452 shares. Palatin Technologies, Inc. (PTN) revealed that after the closing of its licensing contract with AMAG Pharmaceuticals, Inc. (AMAG) for exclusive North American rights to develop and commercialize Rekynda, an investigational product designed for on-demand treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, it will hold a conference call and audio webcast to discuss the licensing contract and next steps for Palatin.
The licensing contract is expected to close in the first quarter of calendar year 2017.The call will discuss Palatin’s role in further development and regulatory approval of Rekynda, and potential licensing transactions outside North America. The call will also discuss Palatin’s anticipated next steps in its other drug development programs, including its melanocortin receptor-¬1 agonist peptides for treatment of inflammatory and dermatologic disease indications, melanocortin receptor-4 agonist compounds for treatment of obesity and diabetes, and natriuretic peptide receptor-¬A agonist compounds for treatment of cardiovascular and pulmonary indications. Its price to sales ratio ended at 1.62. AMAG attains analyst recommendation of 2.00 with week performance of -31.96%.